|
|
November 2026 | Hormones, Peptides & the Year-End Cliff Edition
|
|
In This Issue
Peptides Get a Hall Pass, With Ten Strings Attached. What HHS’s interim enforcement discretion policy does, what it doesn’t, and why your state board still has the final word.
Will Testosterone Come Off the Schedule? Where descheduling actually stands, the legal mechanics nobody is talking about, and why you shouldn’t build a business plan around it yet.
The December 31 Telemedicine Cliff. The DEA flexibilities that let testosterone, ketamine and phentermine be prescribed by video expire in six weeks. Here is how to plan for all three outcomes.
Also on Our Radar and a year-end compliance checklist.
|
|
|
|
| Compounding |
| Peptides Get a Hall Pass, With Ten Strings Attached |
| By Mark Boesen, Pharmacist/Attorney, Boesen & Snow Law |
|
For three years, BPC-157 and a handful of other popular peptides lived in compounding limbo. FDA placed them in Category 2 of its bulk drug substance list in September 2023, citing significant safety concerns, and most 503A pharmacies stopped compounding them. That left a booming gray market of “research use only” vials, frequently sourced overseas, filling the gap.
That changed on October 28, 2026, when HHS filed a notice announcing an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. The notice published in the Federal Register on October 30 (91 FR 68526; Docket HHS-OASH-2026-0496). It was signed by Secretary Kennedy and came from the HHS Office of the Secretary, not from FDA. Under the policy, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound with six peptides, so long as every one of ten conditions is satisfied.
How We Got Here
The road ran through several steps in 2026. In April, the six peptides (along with others) came off Category 2 after their nominations were withdrawn, a move that did not by itself make them eligible for compounding. In July, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted, mostly narrowly, to recommend six of seven reviewed peptides for the 503A bulks list, over CDER’s recommendation against listing any of them. The seventh, emideltide (DSIP), was voted down and is not covered. In mid-October, an interim access policy went to OMB for review, and the final product arrived at the end of the month.
According to press reports, HHS first pursued a rule adding the peptides to the bulks list and turned to enforcement discretion after FDA scientific staff declined to support it. FDA staff did reportedly help draft the quality guardrails that ended up in the policy.
The Six Peptides and Their Permitted Routes
Discretion is tied to a specific salt form, identity, and route for each peptide. A product outside these lines is outside the policy.
| Peptide (form) |
Routes covered by the policy |
| BPC-157 (acetate) | Subcutaneous, intramuscular, oral, and topical |
| TB-500 (acetate) | Subcutaneous or intramuscular injection |
| MOTS-c (acetate) | Subcutaneous or intramuscular injection |
| Epitalon (acetate) | Subcutaneous or intramuscular injection, dispensed in intermittent courses |
| KPV (acetate) | Topical and oral |
| Semax (free base) | Intranasal only |
The Ten Conditions, in Plain English
Enforcement discretion applies only when all ten are met. In summary:
- Approved list only. The bulk substance is one of the six on the policy’s Appendix A.
- Correct identity and route. The substance matches the amino acid sequence, structure, formula, and molecular weight in Appendix B, and the product is for a listed route.
- Registered original manufacturer. The API comes from an FDA-registered, CGMP-compliant original manufacturer, and the manufacturer’s facility location appears on the certificate of analysis. Repackagers and resellers must have validated the manufacturer and its COA.
- Lot-level COA. Each lot carries a COA covering identity, purity, potency, and contaminants, including endotoxins, heavy metals, and microbial testing. A research supplier’s own certificate will not qualify material that cannot be traced back to the original manufacturer.
- Adverse event and quality reporting. Serious adverse events and product quality problems go to FDA MedWatch and to the states where products are made and shipped.
- Single active ingredient. One peptide per product. Premixed “stacks” (for example, BPC-157 plus TB-500 in one vial) do not qualify.
- Required labeling. The label must state that the item is a compounded drug product and not for resale, and identify the ingredient, strength, original manufacturer, dosage form, and route, with patient information on how to report problems.
- Oral bioavailability documentation. For oral dosage forms, the compounder must keep documentation that the specific formulation achieves adequate oral bioavailability in humans. This will be a heavy lift for most oral and sublingual products.
- Syringe-only device. The only co-packaged delivery device permitted is an FDA 510(k)-cleared syringe. No pens or autoinjectors.
- Everything else in 503A still applies. Valid patient-specific prescriptions, no insanitary conditions, and all other applicable FD&C Act requirements.
What the Policy Does Not Do
- It is not an approval or a listing. The six peptides remain unapproved and are not on the 503A bulks list. The policy says it creates no rights, binds neither HHS nor the public, and can be revisited if a safety signal or quality issue emerges.
- It does not cover 503B outsourcing facilities. Clinics cannot buy these as office stock.
- It does not bless “research use only” sales. Selling RUO peptides that are intended for human use remains selling an unapproved drug. In fact, the policy’s stated purpose is to pull demand away from that market.
- It does not change state law. This is the point we expect to generate the most board activity in 2027.
Your State Board Still Gets a Vote
Traditional compounding is regulated primarily by the states, and federal forbearance does not bind a board of pharmacy. Ohio’s board guidance has taken the position that BPC-157 cannot be compounded under state law, and the board has taken action against clinics over peptides. Alabama, Mississippi, and South Carolina have issued their own peptide statements. On the other side, Louisiana passed a 2026 law limiting licensing boards’ ability to block peptide compounding that complies with federal 503A law, though it is an open question whether compounding under an enforcement discretion policy (as opposed to a bulks-list listing) qualifies.
Expect the pressure on state boards to increase. On November 9, the AMA House of Delegates adopted policy urging HHS and FDA to rescind policies easing compounding of unapproved synthetic peptides, and committed to working with state medical and pharmacy boards on enforcement against compounders, telehealth platforms, and online sellers. The Partnership for Safe Medicines has also filed a citizen petition asking FDA not to permit compounding of these peptides through enforcement discretion. A pharmacy that ships nationally needs a state-by-state map, not just a copy of the HHS policy.
What Comes Next
The two-week comment period closed November 13, and HHS has not said whether it will revise the policy in response. The more consequential event will be FDA’s formal rulemaking on the 503A bulks list, which will decide whether each peptide becomes permanently eligible and whether the policy’s extra conditions carry over. FDA has also indicated it will take five more peptides to its advisory committee before the end of February 2027: LL-37, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF. Those five are not covered by the current policy.
|
Practical Takeaways for Pharmacies and Prescribers
Audit your supply chain now. If you cannot trace the API to an FDA-registered original manufacturer with a facility-specific, lot-level COA, you are outside the policy.
Retire the stacks. Combination products do not qualify, even if each ingredient is on the list.
Be skeptical of oral and sublingual products unless you have real human bioavailability data for that formulation.
Check every destination state before you ship, and recheck quarterly. Board positions are moving.
Build a wind-down plan. Discretion can be withdrawn without notice and comment; avoid irreversible investments that assume it will last.
Review your marketing. The policy does not make any peptide safe or effective, and claims that imply FDA endorsement invite trouble.
|
Need help with this issue? Contact an Attorney
|
|
|
| DEA & Controlled Substances |
| Will Testosterone Come Off the Schedule? |
| By Mark Boesen, Pharmacist/Attorney, Boesen & Snow Law |
|
Few regulatory questions generate more calls to our office right now than this one: is testosterone about to be descheduled? The short answer is that the momentum is real, but as of this writing testosterone remains a Schedule III controlled substance, and no formal descheduling action has been proposed by DEA or HHS.
The Timeline So Far
| Date |
Development |
| Feb. 2025 | FDA removed the cardiovascular boxed warning from testosterone products after reviewing the TRAVERSE trial data. |
| Dec. 10, 2025 | FDA convened an expert panel on testosterone therapy. Panelists recommended, among other things, expanding indications to age-related low testosterone and removing testosterone from Schedule III. |
| Feb. 9, 2026 | Public comment period closed, with more than 2,000 comments submitted. |
| Apr. 20, 2026 | FDA published a Federal Register notice inviting holders of approved testosterone applications to discuss expanded indications. |
| June 18, 2026 | HHS announced FDA-requested class-wide labeling changes: removing the age-related hypogonadism limitation of use, narrowing the prostate cancer contraindication to metastatic disease, and revising BPH warnings. These are requests to sponsors; labels change only after FDA approves the supplements. |
| Today | Testosterone is still Schedule III. DEA has not publicly proposed any rescheduling or descheduling action. |
The Legal Mechanics Are Harder Than the Headlines Suggest
Most coverage treats descheduling as something FDA can recommend and DEA can simply do. The statutory structure is more complicated, and it is worth understanding why.
Testosterone did not land on Schedule III through ordinary DEA scheduling. Congress put it there directly in the Anabolic Steroids Control Act of 1990, which added “anabolic steroids” to Schedule III in the statute itself and named testosterone in the statutory definition of anabolic steroid (now at 21 U.S.C. § 802(41)). That creates at least three possible paths, each with different speed and scope:
- Agency rulemaking under 21 U.S.C. § 811. The CSA lets DEA transfer or remove substances from the schedules after receiving a scientific and medical evaluation and recommendation from HHS, through formal rulemaking with an opportunity for a hearing. Because testosterone is embedded in a statutory definition rather than just a schedule listing, any agency-only route will need careful legal footing and could draw a challenge. This is the path to watch, but it is measured in years, not months.
- Congressional action. Congress could amend the definition of anabolic steroid or the schedule. That is the cleanest legal route and the least predictable politically.
- Product-level exemptions under 21 U.S.C. § 811(g)(3)(C). Since 2004, DEA has had authority, on HHS’s recommendation, to exempt specific compounds, mixtures, or preparations containing an anabolic steroid that lack significant abuse potential because of their concentration, formulation, or delivery system. This is narrower than descheduling, but it could move faster for particular dosage forms.
Note for readers: statutory citations in this section should be confirmed against current code before relying on them.
The States Have Their Own Schedules
Even a federal change would not automatically reach state law. Every state maintains its own controlled substances schedule, and many would need to act separately. California is ahead of the curve: AB 1778, which passed the Assembly 77–0, would automatically conform California’s schedule if testosterone or DHT is rescheduled or exempted federally. Expect other states to consider similar trigger provisions in their 2027 sessions, and expect a period in which federal and state status diverge.
What Would and Would Not Change
If descheduled, testosterone would shed DEA registration requirements for that product, Schedule III refill limits, controlled-substance inventory and recordkeeping obligations, and the Ryan Haight Act’s in-person evaluation requirement for telemedicine prescribing. PDMP reporting would depend on each state’s rules.
It would still be a prescription drug. FDA compounding rules would still apply in full, including the 503A limits on compounding drugs that are essentially copies of commercially available products. State boards would still expect prescriptions to rest on a legitimate medical purpose and an appropriate evaluation, and anti-doping rules would be unaffected.
|
Our Advice Right Now
Do not build a compliance program, a pro forma, or an acquisition valuation that assumes testosterone will be descheduled in 2027. Treat it as Schedule III, maintain your DEA and state registrations, keep your inventories reconciled, and document legitimate medical purpose for every prescription. The more pressing testosterone issue is the December 31 telemedicine deadline below.
|
Need help with this issue? Contact an Attorney
|
|
|
| Telemedicine |
| The December 31 Telemedicine Cliff |
| By Mark Boesen, Pharmacist/Attorney, Boesen & Snow Law |
|
The Ryan Haight Act generally requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance by telemedicine. Since 2020, DEA and HHS have waived that requirement through a series of temporary rules. The fourth temporary extension (90 FR 61301, published December 31, 2025) runs through the end of the day on December 31, 2026. After that date, absent further action, the in-person requirement returns.
For our clients, the exposure is concentrated in cash-pay telehealth models built on Schedule III through V drugs: testosterone, ketamine, and phentermine prescribed to patients who have never been seen in person. Pharmacies filling those prescriptions carry corresponding responsibility and should be planning just as actively as prescribers.
Where Things Stand
DEA’s permanent replacement, the special registration for telemedicine first proposed in January 2025, moved to the final rule stage this summer. DEA sent the final rule to OMB’s Office of Information and Regulatory Affairs on August 25, 2026, and the federal regulatory agenda targeted final action for November. As of early November, the rule remained under review, its text has not been made public, and DEA has not announced a fifth extension.
The January 2025 proposal is the best available preview. It would have created three registrations (a general telemedicine prescribing registration for Schedules III–V, an advanced registration for certain specialists that reaches Schedule II, and a platform registration), along with state-by-state DEA telemedicine registrations, PDMP checks, identity verification, and additional reporting. How much of that survives is unknown.
Plan for Three Scenarios
| Scenario |
What it means for January 1 |
| Final rule publishes | New registrations and application steps. Even with a November publication, there may be a gap between January 1 and approved registrations unless DEA builds in a transition period. |
| Fifth extension | Status quo continues. DEA has extended four times, often at the last minute, but nothing has been announced. |
| Nothing happens | The in-person evaluation requirement returns for patients who have not been evaluated in person by the prescribing practitioner. This is the scenario that interrupts care. |
Don’t Forget the State Overlay
Federal flexibility has never overridden stricter state law. Connecticut bars Schedule III prescribing by telehealth; Minnesota and Arkansas require an in-person exam; Louisiana and Alabama require periodic in-person encounters for controlled substances; and Missouri’s HB 2372, effective August 28, 2026, amended its telemedicine prescribing statute in a way that, read literally, reaches first-visit telehealth prescribing without an established relationship. Practices relying solely on the federal extension may already be out of compliance in some states.
|
Six Weeks Out: What to Do Now
Prescribers: run a report of every controlled-substance patient never seen in person, and schedule those visits now. November and December slots are easier to find than the last week of the year.
Pharmacies: identify your telehealth prescriber relationships and talk with them about their plan. Corresponding responsibility does not pause for a regulatory gap.
Everyone: confirm DEA and state controlled substance registrations in every state where patients are located at the time of the encounter.
Documentation: make sure each encounter records the modality (live audio-video for testosterone and phentermine), clinical rationale, labs, and PDMP review.
Contracts: review management, platform, and pharmacy services agreements for regulatory-change and suspension provisions.
Watch the Federal Register weekly. Assign one person to it.
|
Need help with this issue? Contact an Attorney
|
|
|
| Quick Hits |
| Also on Our Radar |
- PBM fee disclosure. A Department of Labor rule recently published in the Federal Register will require PBMs to disclose detailed fee and compensation information to self-insured group health plans, effective January 2027. Pharmacies negotiating with PBMs and plan sponsors should watch how that data gets used.
- More peptides headed to PCAC. LL-37, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF are expected before FDA’s compounding advisory committee before the end of February 2027. Watch for the briefing documents.
- Enforcement against unlicensed shipping. The Ohio Board of Pharmacy recently issued a summary suspension notice to an out-of-state compounding pharmacy over allegations that it shipped unapproved compounded drugs into Ohio, including before obtaining an Ohio license. Nonresident licensure is still the most avoidable violation we see.
- Testosterone labeling supplements. Watch for FDA approval of the class-wide labeling changes requested in June. The last major round of testosterone labeling changes took more than a year and a half to complete.
Need help with these issues? Contact an Attorney
|
|
|
| Self-Check |
| Year-End Compliance Checklist |
| 1. | Can we trace every peptide API to an FDA-registered original manufacturer with a facility-specific, lot-level COA? |
| 2. | Have we discontinued multi-peptide combination products? |
| 3. | Do we have a current, state-by-state map of where peptide compounding is permitted? |
| 4. | Are our MedWatch and state adverse event reporting procedures written down and assigned to a person? |
| 5. | Have we identified every controlled-substance patient who has never had an in-person evaluation? |
| 6. | Do our telehealth prescribers have a plan for January 1, 2027, and have we asked to see it? |
| 7. | Are DEA and state controlled substance registrations current in every state we serve? |
| 8. | Are our testosterone inventories reconciled and our refill practices consistent with Schedule III limits? |
| 9. | Do our contracts address what happens if a regulatory flexibility ends or an enforcement policy is withdrawn? |
| 10. | Has counsel reviewed our marketing for peptide and TRT claims since the October and June announcements? |
Questions on any of this? Contact an Attorney
|
|
|
|
Attorney Advertising. This newsletter is provided for general informational and educational purposes only and does not constitute legal advice. Reading it or contacting Boesen & Snow Law through this newsletter does not create an attorney-client relationship. Please do not send confidential information to Boesen & Snow Law through this newsletter or by replying to it until an attorney-client relationship has been established. This content may constitute attorney advertising under the laws of your state. Prior results described or referenced herein do not guarantee a similar outcome. Laws, regulations, enforcement priorities, and agency policies change frequently and vary by state; the processes, deadlines, and requirements described here may differ depending on the jurisdiction and the agency involved. This issue reflects publicly available information as of November 17, 2026. Consult counsel about your specific situation.
Boesen & Snow Law is based in Scottsdale, Arizona. We work with independent, specialty, and multi-location pharmacies nationwide on PBM audit, network, and compliance matters. Our ability to formally represent a pharmacy in a particular matter, including litigation, arbitration, or before a state board, depends on that jurisdiction’s licensure and admission requirements, which may include pro hac vice admission or association with local counsel. Contact us to confirm we can assist with your pharmacy’s specific state and matter.
Boesen & Snow Law, Scottsdale, Arizona. Website: www.boesensnowlaw.com/contact/
|
|
|